GlassScriptPhysician profile
Melanie W Sims
NPI 1093956351
$2,472.06
in general payments reported to CMS, 2019-2025
21 companies · $1,215 in 2025
The $1,215 reported for 2025 was more than what 90% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $23.30 · 2023: $18.62 · 2024: $1,216 · 2025: $1,215.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,374 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,373.77 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $409.03 | 2024-2025 | Xifaxan, Relistor, Trulance |
| Abbvie INC. | $271.35 | 2024-2025 | |
| Phathom Pharmaceuticals, INC. | $266.18 | 2024-2025 | Voquezna |
| Genzyme Corporation | $264.53 | 2024-2025 | |
| Janssen Biotech, INC. | $228.28 | 2024-2025 | Tremfya, Stelara |
| Aimmune Therapeutics, INC. | $191.82 | 2024-2025 | Zenpep |
| Ardelyx, INC. | $182.08 | 2024-2025 | Ibsrela |
| Pfizer INC. | $164.12 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $77.64 | 2024-2025 | Eohilia, Entyvio |
| Ironwood Pharmaceuticals, INC | $50.05 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $41.92 | 2021-2023 | Andexxa |
| Lilly USA, LLC | $41.41 | 2025 | Omvoh |
| Madrigal Pharmaceuticals | $41.15 | 2024-2025 | Resmetirom, Rezdiffra |
| Ipsen Biopharmaceuticals, INC | $40.63 | 2024-2025 | Iqirvo |
| Regeneron Healthcare Solutions, INC. | $39.38 | 2024-2025 | Dupixent |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $34.12 | 2024 | Zeposia |
| Henry Schein, INC. | $33.52 | 2024 | |
| Qol Medical, LLC | $31.18 | 2024 | Sucraid |
| Orphalan INC | $26.14 | 2025 | Cuvrior |
| Intercept Pharmaceuticals, INC. | $18.99 | 2024 | |
| Organon LLC | $18.54 | 2025 | Hadlima, Renflexis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melanie Sims listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.